Shopping Cart
- Remove All
Your shopping cart is currently empty
KWAR 23
😃Good
Catalog No. T78276Cas No. 2243227-60-1
KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1].
KWAR 23
KWAR 23
😃Good
Catalog No. T78276Cas No. 2243227-60-1
KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | Inquiry | Backorder | |
| 5 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | KWAR23, an anti-human SIRPα antibody, exhibits high-affinity binding to human SIRPα, inhibiting its interaction with CD47. Demonstrating antitumor activity, KWAR23 is efficacious in conjunction with tumor-opsonizing antibodies, making it a valuable agent for cancer immunotherapy research [1]. |
| In vitro | KWAR 23, at concentrations ranging from 0 to 1 μM over a 4-hour exposure, demonstrates antitumor properties by activating human neutrophils and macrophages [1]. Furthermore, it stimulates macrophage-mediated phagocytosis within cell lines derived from human tumors [1]. |
| In vivo | KWAR23, administered via intraperitoneal injection at a dosage of 10 mg/kg biannually for 21 days, demonstrates potent antitumor effects in a human SIRPA knockin mouse model [1]. Additionally, it bolsters the antitumor responses of neutrophils and macrophages in SRG mice [1]. |
| Cas No. | 2243227-60-1 |
Storage & Solubility Information
| Storage | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy KWAR 23 | purchase KWAR 23 | KWAR 23 cost | order KWAR 23 | KWAR 23 in vivo | KWAR 23 in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.